The company said its GAAP earnings for Q3 2024 were $638 million ($1.00 per diluted share), and on an adjusted basis were $566 million ($0.89 per diluted share). Q3 2023 GAAP earnings were $721 million ($1.14 per diluted share), and adjusted earnings were $685 million ($1.08 per diluted share).

1. 01

   The company said its GAAP earnings for Q3 2024 were $638 million ($1.00 per diluted share), and on an adjusted basis were $566 million ($0.89 per diluted share). Q3 2023 GAAP earnings were $721 million ($1.14 per diluted share), and adjusted earnings were $685 million ($1.08 per diluted share).

2. 02

   The company said it excluded the impact of foreign currency and inflation on its monetary positions in Mexico of $67 million from its adjusted results for Q3 2024. For Q3 2023, it excluded $36 million, and for the 9-month cumulative period of 2024, it excluded $178 million.

3. 03

   The company said it updated its full-year 2024 GAAP earnings-per-share outlook to $4.86 to $5.16, affirmed its adjusted EPS outlook of $4.60 to $4.90, and affirmed its 2025 EPS outlook of $4.90 to $5.25. It also put in place an at-the-market (ATM) equity offering program of $3 billion.

4. 04

   The company said it expects a 40-50% increase to Oncor's previously announced 5-year capital plan of $24 billion, and that it will provide an update on the earnings call in February 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.